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Abstract
Regorafenib has improved the survival of patients with refractory metastatic colo-
rectal cancer (mCRC), yet the mechanisms of inherited or acquired resistance are 
not well understood. A total of 50 patients with refractory mCRC were enrolled. 
Circulating tumor cell (CTC) enumeration was carried out at baseline, day 21 after 
initiation of regorafenib, and at the time of progression of disease (PD) using the 
CellSearch System (Veridex LLC, NJ, USA). Poly(A) mRNA was extracted from CTCs, 
and gene expression of epithelial and epithelial-mesenchymal transition markers was 
analyzed by a multiplex-PCR based DNA Chip. Patients with fewer than 3 CTCs at 
baseline and day 21 had a longer progression-free survival than those with 3 or more 
CTCs (3.3 vs 2.0 months, P = .008 and 3.3 vs 2.0 months, P = .004, respectively). 
Patients with fewer than 3 CTCs at baseline and day 21 had a longer overall sur-
vival (OS) than those with 3 or more CTCs (10.0 vs 4.6 months, P < .001 and 8.7 vs 
3.8 months, P = .003, respectively). In multivariable analysis, CTC counts remained 
significantly associated with OS at baseline and day 21 (P = .019 and P = .028). 
Circulating tumor cell EGFR gene expression was upregulated at day 21 and/or PD 
in 64% of patients. Patients had significantly increased EGFR expression at PD com-
pared to baseline (P = .041) and at day 21 and/or PD compared to baseline (P = .004). 
Our findings suggest that CTC count and EGFR expression could be useful markers of 
regorafenib efficacy and outcomes. Upregulation of CTC EGFR expression might be a 
molecular escape mechanism under regorafenib therapy.
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1  | INTRODUC TION
Regorafenib, an oral multikinase inhibitor, blocks the activity of several 
protein kinases, including v-raf murine sarcoma viral oncogene homo-
log B1 (BRAF),1 and improves the progression-free survival (PFS) and 
overall survival (OS) of chemorefractory metastatic colorectal cancer 
(mCRC) patients.1,2 A retrospective exploratory analysis of the pivotal 
phase III CORRECT trial proposed BEAMing analysis of circulating 
DNA as a potential biomarker and viable approach to obtain real-time 
tumor-associated genotypic information in mCRC patients treated 
with regorafenib. Nonetheless, there are currently no validated pre-
dictive or prognostic biomarkers of regorafenib efficacy.
Circulating tumor cells (CTCs) are shed from the primary tumor, 
migrate to sites of metastases, and serve as a noninvasive means of 
monitoring the dynamic alterations driving treatment efficacy and 
disease progression. The most widely studied CTC detection meth-
ods are based on immunomagnetic enrichment with antiepithelial 
cell adhesion molecule (EpCAM) Abs and subsequent immunolog-
ical identification with anticytokeratin (anti-CK). The CellSearch 
system is one such method and is the only FDA-approved assay for 
the enumeration of CTCs in peripheral blood.3-5 In a study by Cohen 
et al using CellSearch, the presence of 3 or more CTCs at baseline 
and follow-up was an independent prognostic marker of inferior 
survival in mCRC patients.5-7 However, it is unclear whether CTC 
enumeration at baseline and over time is predictive or prognostic in 
mCRC patients specifically treated with regorafenib.
In addition to enumeration, protein expression and molecular 
profiling of CTCs might serve as more refined biomarkers and help 
inform a more personalized treatment approach. Under the pressure 
imposed by chemotherapy and mAbs, clonal selection and genomic 
instability emerge and provoke eventual treatment resistance. The 
ability to characterize such intratumoral heterogeneity could help 
to identify novel predictive and prognostic biomarkers and improve 
treatment decision-making. To this end, our group has previously 
examined the prognostic role of epithelial-mesenchymal transition 
(EMT) gene (PI3K, Akt-2, and Twist1) expression within CTCs of pa-
tients with mCRC (Ning Y et al).8
In this study, we examined the ability of CTC enumeration and 
molecular characterization, using mRNA levels of epithelial (EGFR, 
EpCAM, and CEA) and EMT (PI3K, Akt-2, and Twist1) markers, to pre-
dict outcomes and identify potential molecular escape mechanisms 
in mCRC patients undergoing regorafenib therapy.
2  | MATERIAL S AND METHODS
2.1 | Study design and patient population
This was a retrospective analysis of a prospective single-arm study 
examining the efficacy and toxicity of regorafenib in patients with 
refractory mCRC undertaken at the Cancer Institute Hospital of 
the Japanese Foundation for Cancer Research. Eligible patients 
were 18 years or older with histologically confirmed mCRC, who 
had progressed or were intolerant to standard therapy (including a 
fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab, and an an-
tiepidermal growth factor receptor [EGFR] agent if indicated), and 
were subsequently treated with regorafenib at a dose of 160 mg 
orally daily for 21 days of every 28-day cycle. Treatment was con-
tinued until the development of intolerable toxicities or disease 
progression. Standard inclusion criteria applied, including ECOG 
performance status of 0 or 1, presence of measurable disease, life 
expectancy of at least 3 months, and adequate organ function. 
Between March 2013 and December 2014, a total of 62 patients 
were enrolled, of which 50 met inclusion/exclusion criteria and had 
sufficient blood samples for analysis. Study protocols were approved 
by the Institutional Review Board at the Cancer Institute Hospital of 
the Japanese Foundation for Cancer Research. All patients provided 
written informed consent for the evaluation of molecular correlates.
2.2 | Isolation and enumeration of CTCs
Circulating tumor cell enumeration was carried out at baseline 
prior to initiation of regorafenib, day 21 after initiation of therapy, 
and at the time of treatment intolerance or progression of disease 
(PD) using the CellSearch system. A total of 7.5 mL whole blood 
was collected on a CellSave Preservative Tube, and the CellSearch 
Circulating Tumor Cell Kit (Veridex) was applied for CTC enrichment 
and enumeration. Immunomagnetic enrichment was undertaken 
using anti-EpCAM ferrofluid.
Enriched cells were then fluorescently stained with the nucleic 
acid dye DAPI and labeled with mAbs specific for epithelial cells (an-
ti-CK8, 18, and 19) and leukocytes (anti-CD45). A CTC was defined 
as an EpCAM, isolated, intact, round to oval cell, with a visible nu-
cleus (DAPI-positive), positive staining for CK, and negative staining 
for CD45. Results of CTC enumeration were then expressed as the 
number of cells per 7.5 mL blood.9
2.3 | Gene expression analysis using quantitative 
RT-PCR and multiplex PCR
The mRNA expression of epithelial (EGFR, EpCAM, and CEA) and 
EMT (PI3K-α, Akt-2 and, TWIST1) markers in the enriched CTC car-
tridges after counting the CTC number using the CellSearch system 
was measured using the HotStarTaq Master Mix (#203443; Qiagen), 
a thermocycler, and the Agilent 2100 Bioanalyzer on a DNA LabChip 
(Agilent Technologies).
Primers for epithelial (EGFR, EpCAM, and CEA) and EMT (PI3K-α, 
Akt-2, and TWIST1) markers were provided by AdnaGen. The analy-
sis of tumor cell-derived mRNA was carried out by quantitative RT-
PCR for the following transcripts: EGFR, EpCAM, CEA, PI3K-α, Akt-2, 
and TWIST1. AdnaTest ColonCancerDetect and AdnaTest EMT-2/
StemCell Detect kits (AdnaGen), containing oligo(dT)25-coated beads, 
were used to isolate mRNA from tumor cells in the enriched CTC car-
tridges of CellSearch system. PrimerMix ColonDetect was first used 
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to amplify 3 genes (EGFR, EpCAM, and CEA) and 1 control gene (Actin). 
PrimerMix EMT-2/StemCell Detect was used to amplify 3 EMT-
related genes (PI3K-α, Akt-2, and TWIST1) and 1 control gene (Actin). 
Visualization of PCR fragments was carried out with the Agilent 2100 
Bioanalyzer, with a limit of detection of 0.01 ng/μL or more.
2.4 | Statistical analysis
The primary outcome measure was PFS, defined as the date of ran-
domization to the date of first documented disease progression or 
death from any cause. If disease progression or death was not ob-
served, PFS was censored on the day of the last computed tomogra-
phy scan. Secondary end-points were response rate and OS. Overall 
survival was defined as the period from randomization to the date 
of death or censored on the date of last contact if alive. Patients 
were dichotomized into responders (including complete or partial re-
sponse) and nonresponders (including stable or progressive disease) 
as defined by RECIST 1.1 criteria.
Circulating tumor cell levels were dichotomized into low and high 
values based on the widely accepted cut-off value of 3.5 The mRNA 
levels of CTC EGFR, EpCAM, CEA, PI3K-α, Akt-2, and TWIST1 were cat-
egorized into positive and negative groups. The cut-off value of 0.05 
for EGFR expression at baseline was chosen based on the maximum χ2 
approach. Associations between CTC and gene expression levels, and 
PFS and OS were analyzed by Kaplan-Meier curves and log-rank test 
in univariable analysis, and the Cox regression model in a multivariable 
model, adjusting for baseline patient and tumor characteristics.
SAS 9.4 (SAS Institute) was used to perform all analyses. All tests 
were 2-sided at a significance level of .05.
3  | RESULTS
3.1 | Patient and tumor characteristics
Clinicopathologic characteristics are presented in Table 1. The me-
dian follow-up time was 180 days. The median PFS and OS were 
69 days and 192 days, respectively. Six patients were deemed not 
evaluable; 2 patients had rapid disease progression, and 4 patients 
had adverse events. Associations between baseline characteristics 
and clinical outcomes were examined using the log-rank test in uni-
variate analysis. Using the Cox regression model in a multivariable 
model, the presence of liver metastases, metastases to other organs, 
and KRAS mutation status were significantly associated with PFS 
and OS.
3.2 | Clinical outcomes by CTC count and gene 
expression in patients receiving regorafenib
The distribution of CTC count and CTC gene expression at baseline 
and day 21 is outlined in Table 2. At baseline, 64% of patients had 
detectable CTCs, all of whom had measurable CTC EGFR expression. 
Among patients without detectable CTCs, all had measurable mRNA 
expression of at least one of the tested genes at baseline.
TA B L E  1   Patients with metastatic colorectal cancer and tumor 
characteristics (N = 50)
Characteristic N %
Age, y
Median (range) 65 34-78
Sex
M 22 44
F 28 56
Performance status
0 27 54
1 23 46
Primary tumor site
Right 14 28
Left 36 72
Primary tumor resection
No 42 84
Yes 8 16
KRAS mutation status
Wild type 34 69
Mutant 15 31
Metastases
Liver 32 64
Lung 26 52
Lymph nodes 28 56
Peritoneal 12 24
Other organs 13 26
Line of chemotherapy
2 1 2
3 11 22
4 35 70
5 3 6
Response
Complete response 0 0
Partial response 1 2
Stable disease 17 34
Progressive disease 26 52
NE 6 12
Histological type
tub1 11 22
tub2 33 66
por 5 10
Unknown 1 2
aA patient could have multiple sites of metastases.
NE, not evaluable; por, poorly differentiated adenocarcinoma; tub1, 
well-differentiated adenocarcinoma; tub2, moderately differentiated 
adenocarcinoma; 
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Associations between CTC count and outcomes are analyzed 
(Table 3). The CTC count at baseline and at day 21 was signifi-
cantly associated with PFS and OS. Specifically, patients with 
fewer than 3 CTCs at baseline and day 21 had a longer median PFS 
of 3.3 and 3.3 months, respectively, compared to those with 3 or 
more CTCs, who had a median PFS of 2.0 and 2.0 months, respec-
tively (hazard ratio [HR], 2.1 and 2.4; 95% confidence interval [CI], 
1.1-4.2 and 1.0-5.6; P = .008 and P = .004, respectively) (Table 3, 
Figure 1A,1). Patients with less than 3 CTCs at baseline and day 
21 had a longer median OS of 10.0 and 8.7 months, respectively, 
compared with those with 3 or more CTCs, who had a median 
OS of 4.6 and 3.8 months, respectively (HR, 3.0 and 2.5; 95% CI, 
1.5-5.8 and 1.3-4.8; P < .001 and P = .003, respectively) (Table 3, 
Figure 1C,1). In multivariable analysis, CTC counts remained sig-
nificantly associated with OS at baseline and day 21 (HR, 2.7 and 
2.3, adjusted P = .019 and P = .028) (Table 3). Additionally, pa-
tients with less than 3 CTCs at baseline and day 21 had a signifi-
cantly higher tumor response rate compared to those with 3 or 
more CTCs (Fisher’s exact test, P = .007 and P = .03, respectively) 
(Table 3).
We then examined associations between CTC gene expression 
levels and outcomes. We used the optimal cut-off value method as 
previously described.10-12 The cut-off value of 0.05 for EGFR expres-
sion at baseline was chosen based on the maximum χ2 approach. 
Patients with baseline CTC EGFR levels 0.05 or higher had a shorter 
PFS, compared to those with lower levels, both in univariable (HR 
3.20, 95% CI, 1.16-8.80, P = .007) and multivariable (HR 4.26, 95% 
CI, 1.41-11.24, P = .007) analyses. All 5 patients with increased base-
line CTC EGFR expression had disease progression as their best re-
sponse. No significant associations were seen with the other markers 
that were analyzed (Table 3).
3.3 | Changes in CTC count and CTC gene 
expression at day 21
Next, we assessed CTC count and CTC gene expression levels at day 
21 and at the time of disease progression as compared to baseline. 
Circulating tumor cell EGFR expression was significantly increased 
at day 21 and/or PD (P = .004) in 64% of patients (Table 4). More 
specifically, CTC EGFR expression was significantly increased at PD 
compared to baseline (P = .041) in 48% of patients. No significant as-
sociations were seen with the other genes that were analyzed.
3.4 | Associations between changes in CTC 
EGFR and EMT marker expression
We then hypothesized that increased CTC EGFR expression could 
result in an increase in the expression of CTC EMT markers.13 
However, there were no significant associations between changes in 
CTC EGFR and EMT marker gene expression.
4  | DISCUSSION
Our study is the first to show that CTC enumeration and mRNA gene 
expression levels could be useful markers of regorafenib efficacy in 
mCRC patients. Specifically, we found the presence of 3 or more 
CTCs at baseline and day 21 to be an independent prognostic factor 
for inferior survival. Moreover, upregulation of CTC EGFR expression 
induced by regorafenib was associated with disease progression.
Regorafenib blocks both WT and mutant BRAF (V600E) sig-
naling. Preclinical studies have previously indicated that BRAF 
Marker N
No detectable 
expression Median Range
Interquartile 
range
Baseline
CTC count 50 18 2.00 0-105 0-6
EGFR 50 17 0.01 0.00-0.83 0.00-0.02
CEA 50 24 0.01 0.00-0.51 0.00-0.01
EpCAM 50 39 0.00 0.00-2.11 0.00-0.00
TWIST1 50 36 0.00 0.00-0.06 0.00-0.01
Akt2 49 38 0.00 0.00-0.48 0.00-0.00
PI3Kα 50 42 0.00 0.00-0.06 0.00-0.00
Day 21
CTC Count 50 20 1.00 0-346 0-4
EGFR 50 25 0.01 0.00-1.48 0.00-0.01
CEA 50 37 0.00 0.00-0.02 0.00-0.01
EpCAM 50 40 0.00 0.00-0.02 0.00-0.00
TWIST1 49 39 0.00 0.00-0.21 0.00-0.00
Akt2 50 39 0.00 0.00-0.02 0.00-0.00
PI3Kα 50 43 0.00 0.00-0.02 0.00-0.00
TA B L E  2   Circulating tumor cell (CTC) 
count and gene expression distribution
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inhibition causes feedback activation of EGFR signaling and in-
creased EGFR expression, allowing for ongoing tumor cell prolif-
eration.14 In previous studies, tumor tissue EGFR expression has 
been shown to be a negative prognostic marker.15 Our data further 
support these findings, suggesting that regorafenib therapy could 
increase EGFR expression and signaling to an extent that leads to 
molecular escape and treatment resistance. Patients with baseline 
CTC EGFR levels 0.05 or higher had a shorter PFS and had dis-
ease progression at the time of their first radiographic evaluation. 
Although the findings of this study are hypothesis generating, if 
validated in future studies, CTC EGFR expression could serve as a 
useful marker to identify patients resistant to regorafenib prior to 
start of therapy.
Importantly, we investigated CTC gene expression levels in 
patients with and without detectable CTCs, as defined by the 
CellSearch assay. A subgroup of patients without detectable CTCs 
according to CellSearch criteria had expression of epithelial marker 
genes, suggesting the presence of circulating tumor load, CTCs or cell 
fragments like exosomes, which were not detected or recognized by 
the CellSearch system. Similarly, in a study by Mostert et al,16 CRC 
patients without detectable CTCs were found to have a circulating 
F I G U R E  1   Comparison of clinical outcomes by circulating tumor cell (CTC) count at baseline and day 21 of treatment with regorafenib 
in patients with metastatic colorectal cancer. A,B, Progression-free survival probability at (A) baseline and (B) day 21. C,D, Overall survival 
probability at (C) baseline and (D) day 21
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TA B L E  4   Circulating tumor cell EGFR upregulation compared to 
baseline value in patients with metastatic colorectal cancer treated 
with regorafenib (N = 50)
 Day 21 PD Day 21 and/or PD
Increased ≥0.01 ng/
µL, n (%)
14 (28) 24 (48) 32 (64)
Stable/decreased, 
n (%)
36 (72) 17 (34) 18 (36)
Pa .600 .041 .004
Abbreviation: PD, progressive disease.
aBased on the sign test for paired data. 
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tumor mRNA profile, distinct from both patients with 3 or more de-
tectable CTCs and healthy donors, further suggesting that the blood 
of patients with no CTCs by CellSearch can contain CTCs or frag-
ments. In patients without detectable CTCs by CellSearch criteria, 
exosomes could still be present, because CTC isolation is preceded 
by a Ficoll-based density gradient enrichment.16 Taken together, our 
findings highlight a limitation of relying on CTC count alone as a bio-
marker, and the importance of circulating mRNA expression as a po-
tential prognostic marker in mCRC patients treated with regorafenib.
Furthermore, a considerable proportion of patients in our study 
did not have detectable CTCs at baseline or subsequent follow-up. 
Previous reports suggest that CRC cells can lack CK8, 18, or 19 ex-
pression, the markers by which a CTC is defined in CellSearch, reflect-
ing the EMT-like phenotype of these cells.17,18 A lack of CK8, 18, or 19 
expression would not affect the isolation of CTCs by immunomagnetic 
enrichment, which is based on their EpCAM expression. However, the 
lack of cytokeratin expression could result in these cells not being 
identified as epithelial cells and thus not counted as CTCs in the sub-
sequent enumeration step. Therefore, in addition to the presence of 
cell fragments (eg exosomes), another possible explanation for the lack 
of detectable CTCs according to CellSearch criteria could be the insuf-
ficient expression of epithelial markers (ie CK8, 18, and 19).
It has been reported that CTCs often exist in a state of EMT or 
could coexpress both epithelial and mesenchymal markers. During 
the EMT, epithelial cells downregulate epithelial-related genes, ac-
quire mesenchymal gene expression, and undergo major changes in 
their cytoskeleton that result in loss of cell-cell contact and cell polar-
ity, leading to increased motility and invasiveness.19 Here, we inves-
tigated the expression of CTC EMT markers, including TWIST1, Akt2, 
and PI3Kα, as well as associations between CTC EGFR and EMT gene 
expression, and found a nonsignificant trend towards an inverse as-
sociation. The lack of a significant association could reflect challenges 
associated with CTC characterization using the CellSearch technique, 
including the presence of an excess of leukocytes, which express 
EMT marker genes, in CTC-enriched blood fractions.
Certain limitations of our study should be acknowledged. Our 
data are limited by the small sample size and are only exploratory. 
The lack of a control group of patients not receiving regorafenib pre-
clude any conclusions that can be drawn regarding the use of CTC 
count or associated EGFR expression as predictive markers.
In summary, we identified CTC count as a prognostic marker in 
mCRC patients treated with regorafenib. Circulating tumor cell EGFR 
expression was significantly increased with regorafenib at the time 
of disease progression, suggesting this to be a mode of resistance 
and lending further mechanistic evidence for the synergistic effects 
seen with regorafenib and anti-EGFR mAbs.20 Our findings warrant 
further investigation and, if replicated in future investigations, could 
inform the selection of mCRC patients best suited for regorafenib in 
the chemorefractory setting.
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